Navigation Links
Europe's Columbus laboratory leaves Earth
Date:2/7/2008

ence payloads, this will be a great day for Europe, and I see this day coming very soon now said the ESA Director General, Jean-Jacques Dordain. Its been a long road since the early days of our Spacelab laboratory onboard the Space Shuttle. With Columbus and the upcoming ATVs, weve grown from the status of passenger to that of fully-fledged partner. For the first time, a European-manned facility will be permanently operated in orbit, under the control of a European centre. The know-how we acquired to reach this point will be of tremendous importance in preparing for the future of human space flight, in Earth orbit and beyond, with our international partners. I wish to pay tribute to all the teams at ESA and the industrial contractors in Europe for this success as well as to ESAs Member States, which, in spite of all the changes in the configuration of the ISS throughout the years, have lent their support to allow ESA to become a highly trustworthy partner in this endeavour. I take the opportunity also to acknowledge NASA, its Administrator and all his teams involved in this extraordinary achievement, for their dedication in maintaining a robust schedule in their difficult task of assembling the International Space Station.

Space Shuttle Atlantis is due to undock from the ISS on 16 February and to land back in Florida two days later.

Unlike the other crew-members of the STS-122 missions, Lopold Eyharts is due to remain onboard the station, trading places with NASA astronaut Dan Tani as a member of the 16th permanent crew of the ISS. While on the station, Lopold Eyharts will proceed with the commissioning of Columbus and the first experiments onboard. He will return to Earth in about two months with the next shuttle flight, STS-123, currently scheduled for launch on 11 March for a 16 day mission.

Depending on traffic planning at the ISS, Lopold Eyharts could still be onboard the ISS when the 'Jules Verne' ATV arrives, with its first load
'/>"/>

Contact: media.relations@esa.int
33-153-697-299
European Space Agency
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Knights of Columbus to Distribute Wheelchairs to Veterans in Need
2. Columbus Carried Syphilis From New World to Europe, Study Suggests
3. Laboratory at UI plays major role in diagnosing cancer
4. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
5. Epilepsy-induced brain cell damage prevented in the laboratory
6. Story tips from the Department of Energys Oak Ridge National Laboratory, Nov. 2007
7. ThalesNano Inc. and the Christian Doppler Laboratory for Microwave Chemistry in Graz, Austria Collaborate on Flow Chemistry Technologies
8. MCG selected as RNA laboratory for worldwide diabetes study
9. Inverness Medical Innovations to Acquire Redwood Toxicology Laboratory
10. Novel anticancer strategy moves from laboratory to clinic
11. Tethys Bioscience Hits Key Milestones With Series C Funding, Opening of CLIA Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 1Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 2Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 3Herley Industries Inc Reports Third Quarter Earnings 48677 1Herley Industries Inc Reports Third Quarter Earnings 48677 2Herley Industries Inc Reports Third Quarter Earnings 48677 3Herley Industries Inc Reports Third Quarter Earnings 48677 4Herley Industries Inc Reports Third Quarter Earnings 48677 5Herley Industries Inc Reports Third Quarter Earnings 48677 6Herley Industries Inc Reports Third Quarter Earnings 48677 7Herley Industries Inc Reports Third Quarter Earnings 48677 8Herley Industries Inc Reports Third Quarter Earnings 48677 9Herley Industries Inc Reports Third Quarter Earnings 48677 10Herley Industries Inc Reports Third Quarter Earnings 48677 11Herley Industries Inc Reports Third Quarter Earnings 48677 12Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 1Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 2